Shah S, Nandy R, Sethi S, Chavan B, Pathak S, Dutta S
Lancet Reg Health Southeast Asia. 2023; 19:100256.
PMID: 38076719
PMC: 10709676.
DOI: 10.1016/j.lansea.2023.100256.
Islam M, Date K, Khan A, Bhuiyan T, Khan Z, Ahmed S
Clin Infect Dis. 2022; 76(2):263-270.
PMID: 36136760
PMC: 9839191.
DOI: 10.1093/cid/ciac782.
Chowdhury F, Ross A, Islam M, McMillan N, Qadri F
Clin Microbiol Rev. 2022; 35(3):e0021121.
PMID: 35726607
PMC: 9491185.
DOI: 10.1128/cmr.00211-21.
Holmgren J
J Infect Dis. 2021; 224(12 Suppl 2):S742-S748.
PMID: 34453544
PMC: 8687080.
DOI: 10.1093/infdis/jiab423.
Deen J, Clemens J
Trop Med Infect Dis. 2021; 6(1).
PMID: 33803390
PMC: 8005943.
DOI: 10.3390/tropicalmed6010032.
Vaccines against gastroenteritis, current progress and challenges.
Seo H, Duan Q, Zhang W
Gut Microbes. 2020; 11(6):1486-1517.
PMID: 32552414
PMC: 7524147.
DOI: 10.1080/19490976.2020.1770666.
Willingness to pay for oral cholera vaccines in urban Bangladesh.
Sarker A, Islam Z, Sultana M, Sheikh N, Mahumud R, Islam M
PLoS One. 2020; 15(4):e0232600.
PMID: 32353086
PMC: 7192494.
DOI: 10.1371/journal.pone.0232600.
Global oral cholera vaccine use, 2013-2018.
Pezzoli L
Vaccine. 2019; 38 Suppl 1:A132-A140.
PMID: 31519444
PMC: 10967685.
DOI: 10.1016/j.vaccine.2019.08.086.
Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Mohan V, Raj S, Dhingra M, Aloysia DCor N, Singh A, Saluja T
PLoS One. 2019; 14(6):e0218033.
PMID: 31211792
PMC: 6581248.
DOI: 10.1371/journal.pone.0218033.
Factors That Influence the Immune Response to Vaccination.
Zimmermann P, Curtis N
Clin Microbiol Rev. 2019; 32(2).
PMID: 30867162
PMC: 6431125.
DOI: 10.1128/CMR.00084-18.
IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity.
Yang J, An S, Jang M, Song M, Han S
PLoS One. 2019; 14(3):e0213507.
PMID: 30845262
PMC: 6405115.
DOI: 10.1371/journal.pone.0213507.
The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships.
Odevall L, Hong D, Digilio L, Sahastrabuddhe S, Mogasale V, Baik Y
Vaccine. 2018; 36(45):6606-6614.
PMID: 30314912
PMC: 6203809.
DOI: 10.1016/j.vaccine.2018.09.026.
Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
Cordero De Los Santos L, Feris-Iglesias J, Aloysia DCor N, Midde V, Patnaik B, Thollot Y
Hum Vaccin Immunother. 2018; 14(6):1403-1411.
PMID: 29470934
PMC: 6037475.
DOI: 10.1080/21645515.2018.1430540.
Causes of impaired oral vaccine efficacy in developing countries.
Parker E, Ramani S, Lopman B, Church J, Iturriza-Gomara M, Prendergast A
Future Microbiol. 2017; 13:97-118.
PMID: 29218997
PMC: 7026772.
DOI: 10.2217/fmb-2017-0128.
Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.
Kim K, Jeong S, Ahn K, Yang J, Yun C, Han S
J Microbiol. 2017; 55(12):973-978.
PMID: 29214494
DOI: 10.1007/s12275-017-7478-0.
Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.
Lopez A, Deen J, Azman A, Luquero F, Kanungo S, Dutta S
Clin Infect Dis. 2017; 66(12):1960-1971.
PMID: 29177437
PMC: 5982790.
DOI: 10.1093/cid/cix1039.
Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding M, Gonzales M, Dhingra M, Aloysia DCor N, Midde V, Patnaik B
Hum Vaccin Immunother. 2017; 13(10):2232-2239.
PMID: 28910563
PMC: 5975480.
DOI: 10.1080/21645515.2017.1342908.
Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
Desai S, Pezzoli L, Alberti K, Martin S, Costa A, Perea W
Hum Vaccin Immunother. 2016; 13(3):579-587.
PMID: 27813703
PMC: 5360144.
DOI: 10.1080/21645515.2016.1245250.
Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults.
Matias W, Falkard B, Charles R, Mayo-Smith L, Teng J, Xu P
PLoS Negl Trop Dis. 2016; 10(6):e0004753.
PMID: 27308825
PMC: 4911095.
DOI: 10.1371/journal.pntd.0004753.
A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
Desai S, Akalu Z, Teshome S, Teferi M, Yamuah L, Kim D
Am J Trop Med Hyg. 2015; 93(3):527-533.
PMID: 26078323
PMC: 4559691.
DOI: 10.4269/ajtmh.14-0683.